New bladder cancer drug shows early promise in small trial
Disease control
Completed
This early-phase trial tested a new drug called UGN-301 (zalifrelimab) given directly into the bladder for people with recurrent non-muscle invasive bladder cancer. The study included 51 participants and aimed to check safety and find the right dose, both alone and with other dru…
Phase: PHASE1 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC